Cargando…

Impact of luteinizing hormone suppression on hematopoietic recovery after intensive chemotherapy in patients with leukemia

Treatment of acute leukemia with intensive chemotherapy leads to an increased risk of myelosuppression. Luteinizing hormone (LH) blockade improves hematopoietic recovery in mice after radiation or chemotherapy, through protection of the hematopoietic stem cells which express the LH receptor. We hypo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dalle, Iman Abou, Paranal, Ronald, Zarka, Jabra, Paul, Shilpa, Sasaki, Koji, Li, Wen, Ning, Jing, Short, Nicholas J., Ohanian, Maro, Cortes, Jorge E., Jabbour, Elias J., Issa, Ghayas C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586820/ https://www.ncbi.nlm.nih.gov/pubmed/33297667 http://dx.doi.org/10.3324/haematol.2020.256453

Ejemplares similares

Nucleophosmin 1 Mutations in Acute Myeloid Leukemia
por: Zarka, Jabra, et al.
Publicado: (2020)

Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
por: Abou Dalle, Iman, et al.
Publicado: (2019)

Evaluation and management of measurable residual disease in acute lymphoblastic leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

P687: EARLY RESULTS OF A PHASE II STUDY EVALUATING THE ADDITION OF ASCIMINIB TO ERADICATE MINIMAL RESIDUAL DISEASE IN CHRONIC MYELOID LEUKEMIA
por: Bidikian, Aram, et al.
Publicado: (2023)

New option for improving hematological recovery: suppression of luteinizing hormone
por: Elias, Harold K., et al.
Publicado: (2020)

Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia
por: Bidikian, Aram, et al.
Publicado: (2022)

Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements
por: Issa, Ghayas C., et al.
Publicado: (2021)

P672: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH CHRONIC MYELOID LEUKEMIA AND T315I MUTATION AFTER FAILURE OF PRIOR THERAPIES
por: Bidikian, Aram, et al.
Publicado: (2023)

Management of chronic myeloid leukemia in 2023 – common ground and common sense
por: Senapati, Jayastu, et al.
Publicado: (2023)

The Elephant in The Room: AML Relapse Post Allogeneic Hematopoietic Cell Transplantation
por: Abou Dalle, Iman, et al.
Publicado: (2022)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Hypomethylating agent and venetoclax with FLT3 inhibitor “triplet” therapy in older/unfit patients with FLT3 mutated AML
por: Yilmaz, Musa, et al.
Publicado: (2022)

Response of the corpus luteum to luteinizing hormone.
por: Niswender, G D
Publicado: (1981)

Impact of frontline treatment approach on outcomes of myeloid blast phase CML
por: Saxena, Kapil, et al.
Publicado: (2021)

Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents
por: Hammond, Danielle, et al.
Publicado: (2023)

Impact of numerical variation, allele burden, mutation length and co-occurring mutations on the efficacy of tyrosine kinase inhibitors in newly diagnosed FLT3- mutant acute myeloid leukemia
por: Abou Dalle, Iman, et al.
Publicado: (2020)

Luteinizing hormone and its dilemma in ovulation induction
por: Kumar, Pratap, et al.
Publicado: (2011)

Ganirelix and the prevention of premature luteinizing hormone surges
por: Mannaerts, Bernadette
Publicado: (2023)

Luteinizing hormone beta gene polymorphism and its effect on semen quality traits and luteinizing hormone concentrations in Murrah buffalo bulls
por: Reen, Jagish Kour, et al.
Publicado: (2018)

Calibration-free NGS quantitation of mutations below 0.01% VAF
por: Dai, Peng, et al.
Publicado: (2021)

The utilization of basal luteinizing hormone in combination with the basal luteinizing hormone and follicle-stimulating hormone ratio as a diagnostic tool for central precocious puberty in girls
por: Chotipakornkul, Nuntika, et al.
Publicado: (2023)

Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype
por: Samra, Bachar, et al.
Publicado: (2020)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

Do basal Luteinizing Hormone and Luteinizing Hormone/Follicle-Stimulating Hormone Ratio Have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Singh, Neeta, et al.
Publicado: (2021)

Do Basal Luteinizing Hormone and Luteinizing Hormone/ Follicle-Stimulating Hormone Ratio have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Neeta, Singh, et al.
Publicado: (2021)

Do Basal Luteinizing Hormone and Luteinizing Hormone/Follicle- Stimulating Hormone Ratio have Significance in Prognosticating the Outcome of In vitro Fertilization Cycles in Polycystic Ovary Syndrome?
por: Sookaromdee, Pathum, et al.
Publicado: (2021)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
por: Short, Nicholas J., et al.
Publicado: (2023)

Genetic Models for the Study of Luteinizing Hormone Receptor Function
por: Narayan, Prema
Publicado: (2015)

Expression of the luteinizing hormone receptor (LHR) in ovarian cancer
por: Xiong, Shigang, et al.
Publicado: (2019)

Azacitidine in Combination with Venetoclax Maintenance Post-allogeneic Hematopoietic Stem Cell Transplantation in T Cell Acute Lymphoblastic Leukemia
por: Hassan, Mona Ali, et al.
Publicado: (2023)

Serum luteinizing hormone level and luteinizing hormone/follicle-stimulating hormone ratio but not serum anti-Müllerian hormone level is related to ovarian volume in Korean women with polycystic ovary syndrome
por: Chun, Sungwook
Publicado: (2014)

Pharmacologic Therapies to Prevent Relapse of Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
por: Antar, Ahmad I., et al.
Publicado: (2020)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

The Roles of Luteinizing Hormone, Follicle-Stimulating Hormone and Testosterone in Spermatogenesis and Folliculogenesis Revisited
por: Oduwole, Olayiwola O., et al.
Publicado: (2021)

The crystal structure of the β subunit of luteinizing hormone and a model for the intact hormone
por: Larson, Steven B., et al.
Publicado: (2019)

Patient characteristics predicting prolonged length of hospital stay following robotic-assisted radical prostatectomy
por: Hajj, Albert El, et al.
Publicado: (2022)

Novel strategies to prevent and overcome relapse after allogeneic hematopoietic cell transplantation in acute lymphoblastic leukemia
por: Hodroj, Mohammad Hassan, et al.
Publicado: (2023)

Kisspeptin mediation of estradiol-induced secretion of luteinizing hormone and prolactin
por: Toporikova, Natalia, et al.
Publicado: (2014)

Expression of Luteinizing Hormone (LH) Subunit Genes in Mouse Testis
por: Kim, Hee Soo, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_9oo46f13c0bofujk9gbn998v2e